WaveMan
WaveMan · Company
PHVS · Pharvaris N.V.
> Search tickers & screens ⌘K
LIVE
← All companies

PHVS Pharvaris (PHVS) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001830487
Quote by TradingView
Form 144 · 17
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
74
13F, latest reported quarter
Conversions, 180 days
31
Codes C/M, not in net · $14.6M priced

What the filings say about PHVS

Insiders, 180 days
-$28.3M net sold
11 sellers · 17% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$30.8M
17 notices

Pharvaris insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Pharvaris N.V. insiders sold a net $28.3M of stock across 68 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.

Insider
Filed
Shares
Value
Since filing
Monges Viviane
Director
SELL
2026-09-25 SECtraded 2026-09-23
11,969
$395.5K
-1.2%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on May 21, 2026.
  • The trade is 217.6% of the 5,500 shares held after it.
  • 9 other insiders sold within 30 days.
  • 74 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Monges Viviane sold about $395.5K of PHVS on Sep 23, 2026; 9 other insiders sold within 30 days and 74 funds added in the latest 13F quarter.
Schikan Johannes Gerardus Christiaan Petrus
Director
SELL
2026-09-24 SECtraded 2026-09-22
800
$29.0K
-1.5%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Sep 17, 2026.
  • The trade is 0.7% of the 115,167 shares held after it.
  • 9 other insiders sold within 30 days.
  • 74 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Schikan Johannes Gerardus Christiaan Petrus sold about $29.0K of PHVS on Sep 22, 2026; 9 other insiders sold within 30 days and 74 funds added in the latest 13F quarter.
Nassif David W.
CFO / CLO
SELL
2026-09-23 SECtraded 2026-09-21
6,000
$218.8K
-4.4%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on May 21, 2026.
  • The trade is 5.2% of the 114,300 shares held after it.
  • 9 other insiders sold within 30 days.
  • 74 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO / CLO Nassif David W. sold about $218.8K of PHVS on Sep 21, 2026; 9 other insiders sold within 30 days and 74 funds added in the latest 13F quarter.
Lesage Anne
Chief Early Development
SELL
2026-09-21 SECtraded 2026-09-17
20,000
$765.5K
-10.4%
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Sep 10, 2026.
  • The trade is 27.0% of the 73,969 shares held after it.
  • 9 other insiders sold within 30 days.
  • 74 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Early Development Lesage Anne sold about $765.5K of PHVS on Sep 17, 2026; 9 other insiders sold within 30 days and 74 funds added in the latest 13F quarter.
Glassman Robert
Director
SELL
2026-09-21 SECtraded 2026-09-17
14,493
$558.8K
-10.4%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Sep 15, 2026.
  • The trade is 138.0% of the 10,500 shares held after it.
  • 9 other insiders sold within 30 days.
  • 74 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Glassman Robert sold about $558.8K of PHVS on Sep 17, 2026; 9 other insiders sold within 30 days and 74 funds added in the latest 13F quarter.
68 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 63 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$28.3M over 180 days
-$20.4M over 90 days
below 90% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
74 funds bought in last quarter
more than 58% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
5.6% of the float short (float per yahoo 2026-10-27) · 4.0 days to cover · settled 2026-10-15
below 55% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch PHVS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+37.1%12M
-6%+19%+44%+69%2025-102025-122026-022026-042026-062026-082026-10 2026-09-17 · Schikan Johannes Gerardus Christiaan Petrus sold $7.0M2026-09-17 · Lu Peng sold $3.5M2026-09-17 · Bjork Elisabeth sold $2.0M2026-09-15 · Abele Stefan Andreas sold $1.7M2026-09-10 · Lesage Anne sold $1.1M2026-06-30 · Schikan Johannes Gerardus Christiaan Petrus sold $1.1M2026-06-30 · Lesage Anne sold $1.1M2026-06-30 · Lesage Anne sold $988.9K2026-04-30 · Schikan Johannes Gerardus Christiaan Petrus sold $860.5K2026-09-14 · Souverijns Wim sold $786.1K2026-09-17 · Lesage Anne sold $765.5K2026-04-09 · Modig Berndt sold $641.7K2026-09-08 · Lu Peng sold $610.1K2026-09-11 · Lu Peng sold $601.9K2026-04-30 · Lesage Anne sold $581.0K2026-09-17 · Glassman Robert sold $558.8K2026-04-30 · Lesage Anne sold $544.7K2026-06-26 · Lu Peng sold $499.8K2026-04-30 · Lu Peng sold $453.6K2026-05-01 · Lu Peng sold $422.9K2026-06-25 · Lu Peng sold $399.6K2026-09-23 · Monges Viviane sold $395.5K2026-09-15 · Glassman Robert sold $331.7K2026-05-21 · Nassif David W. sold $303.1K2026-09-09 · Glassman Robert sold $300.4K2026-05-15 · Souverijns Wim sold $299.2K2026-05-20 · Bjork Elisabeth sold $293.2K2026-05-21 · Monges Viviane sold $292.8K2026-06-29 · Lesage Anne sold $290.9K2026-05-15 · Abele Stefan Andreas sold $260.9K2026-06-29 · Lesage Anne sold $245.2K2026-06-29 · Schikan Johannes Gerardus Christiaan Petrus sold $241.4K2026-09-15 · Souverijns Wim sold $237.4K2026-09-21 · Nassif David W. sold $218.8K2026-04-22 · Lu Peng sold $210.4K2026-04-22 · Schikan Johannes Gerardus Christiaan Petrus sold $210.3K2026-04-22 · Lesage Anne sold $210.3K2026-05-22 · Nijdam Anna sold $169.1K2026-05-15 · Glassman Robert sold $159.1K2026-05-15 · Glassman Robert sold $139.2K2026-06-25 · Lu Peng sold $119.3K2026-04-29 · Schikan Johannes Gerardus Christiaan Petrus sold $115.2K2026-09-23 · VIVIANE ROSINE FRANCOISE BECK MONGES filed to sell $395.5K2026-09-22 · JOHANNES GER. CHRIS. PE SCHIKAN filed to sell $29.0K2026-09-21 · DAVID NASSIF filed to sell $218.8K2026-09-17 · ELISABETH E. BJORK filed to sell $2.0M2026-09-17 · ROBERT GLASSMAN filed to sell $558.8K2026-09-17 · GRAYMATTERS CONSULTING filed to sell $765.5K2026-09-17 · PENG LU filed to sell $3.5M2026-09-17 · SCHOODIC MANAGEMENT BV filed to sell $10.5M2026-09-17 · JOHANNES GER. CHRIS. PE SCHIKAN filed to sell $7.0M2026-09-15 · STEFAN ABELE filed to sell $1.8M2026-09-15 · ROBERT GLASSMAN filed to sell $331.7K2026-09-14 · Berndt B.A,E. Modig filed to sell $87.1K2026-09-14 · WIM SOUVERIJNS filed to sell $1.0M2026-09-10 · ANNE LESAGE filed to sell $1.1M2026-09-09 · ROBERT R. GLASSMAN filed to sell $300.4K2026-09-08 · PENG LU filed to sell $1.1M2026-08-14 · Berndt B.A,E. Modig filed to sell $78.0K2026-07-13 · Berndt B.A,E. Modig filed to sell $80.4K2026-06-30 · ANNE SIMONNE J. LESAGE filed to sell $967.4K2026-06-30 · GrayMatters Consulting B.V. filed to sell $1.1M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns PHVS: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
6,565,272 sh
$227.0M
GENERAL ATLANTIC, L.P.
6,550,757 sh
$226.5M
Foresite Capital Management IV, LLC
4,778,581 sh
$165.2M
venBio Partners LLC
4,643,430 sh
$160.6M
VIKING GLOBAL INVESTORS LP
3,653,310 sh
$126.3M

Congress trades in PHVS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

PHVS planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
VIVIANE ROSINE FRANCOISE BECK MONGES
Filed 2026-09-23
$395.5K
JOHANNES GER. CHRIS. PE SCHIKAN
Filed 2026-09-22
$29.0K
DAVID NASSIF
Filed 2026-09-21
$218.8K
ELISABETH E. BJORK
Filed 2026-09-17
$2.0M
ROBERT GLASSMAN
Filed 2026-09-17
$558.8K

PHVS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
ALPS Medical Breakthroughs ETF
$2.0M position · as of 2026-05-31
1.2%
iShares MSCI Netherlands ETF
$1.2M position · as of 2026-05-31
0.2%
Small Cap Stock Trust
$606.7K position · as of 2026-06-30
0.2%
Invesco Nasdaq Biotechnology ETF
$103.8K position · as of 2026-05-31
0.2%
Health Sciences Trust
$230.6K position · as of 2026-06-30
0.1%
T. Rowe Price Innovation Leaders ETF
$9.7K position · as of 2026-06-30
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $28.3M sold by insiders over 180 days, 74 funds added last quarter, $30.8M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

PHVS financials

Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Net income-$175.7M-$134.2M-$100.9M-$76.3M
SEC XBRL, fiscal years, as known on 2026-10-28

PHVS Stock Sonar score 3/7 axes

Find similar shapesCompare

PHVS ranks highest on institutional and government (58th percentile) and risk and compliance (56th), and lowest on insider conviction (4th), among Pharma & Biotech peers.

Insider conviction
4
Inputs
  • Net Form 4 buying (codes P and S), 180d-$24.2M · 8 pct, sector of 429
  • Insider buyers, 180d0 · 0 pct, sector of 438
Institutional and government
58
Inputs
  • Funds adding, latest quarter74 · 58 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
56
Inputs
  • Short interest, % of float+5.6% · 56 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Profitability, Financial health, Growth, US patents
  • Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

PHVS filings, in plain words

Are Pharvaris insiders buying or selling PHVS?

In the 180 days to 2026-10-28, Pharvaris insiders were net sellers, a net $28.3M across purchases and sales reported on Form 4, by 11 sellers.

Are there planned insider sales of PHVS?

Yes. 17 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $30.8M of stock; the latest, by VIVIANE ROSINE FRANCOISE BECK MONGES, was filed 2026-09-23.

Read the full summary

In the 180 days to 2026-10-28, Pharvaris insiders were net sellers of PHVS, a net $28.3M across purchases and sales reported on Form 4 by 11 sellers. 17% of the 48 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 17 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $30.8M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies